Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2018

Open Access 01-12-2018 | Review

Fibroblasts as a practical alternative to mesenchymal stem cells

Authors: Thomas E. Ichim, Pete O’Heeron, Santosh Kesari

Published in: Journal of Translational Medicine | Issue 1/2018

Login to get access

Abstract

Mesenchymal stem cell (MSC) therapy offers great potential for treatment of disease through the multifunctional and responsive ability of these cells. In numerous contexts, MSC have been shown to reduce inflammation, modulate immune responses, and provide trophic factor support for regeneration. While the most commonly used MSC source, the bone marrow provides relatively little starting material for cellular expansion, and requires invasive extraction means, fibroblasts are easily harvested in large numbers from various biological wastes. Additionally, in vitro expansion of fibroblasts is significantly easier given the robustness of these cells in tissue culture and shorter doubling time compared to typical MSC. In this paper we put forward the concept that in some cases, fibroblasts may be utilized as a more practical, and potentially more effective cell therapy than mesenchymal stem cells. Anti-inflammatory, immune modulatory, and regenerative properties of fibroblasts will be discussed in the context of regenerative medicine.
Literature
1.
Friedenstein AJ, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2(2):83–92.PubMed
2.
Friedenstein AJ, et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17(4):331–40.PubMedCrossRef
3.
Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276(5309):71–4.PubMedCrossRef
4.
Friedenstein AJ, et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6(2):230–47.PubMedCrossRef
5.
Zannettino AC, et al. Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. J Cell Physiol. 2008;214(2):413–21.PubMedCrossRef
6.
Hoogduijn MJ, et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev. 2007;16(4):597–604.PubMedCrossRef
7.
Chao KC, et al. Islet-like clusters derived from mesenchymal stem cells in Wharton’s Jelly of the human umbilical cord for transplantation to control type 1 diabetes. PLoS ONE. 2008;3(1):e1451.PubMedPubMedCentralCrossRef
8.
Jo YY, et al. Isolation and characterization of postnatal stem cells from human dental tissues. Tissue Eng. 2007;13(4):767–73.PubMedCrossRef
9.
He Q, Wan C, Li G. Concise review: multipotent mesenchymal stromal cells in blood. Stem Cells. 2007;25(1):69–77.PubMedCrossRef
10.
Oh W, et al. Immunological properties of umbilical cord blood-derived mesenchymal stromal cells. Cell Immunol. 2008;251:116–23.PubMedCrossRef
11.
12.
Hida N, et al. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells. 2008;26:1695–704.PubMedCrossRef
13.
Patel AN, et al. Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation. Cell Transplant. 2008;17(3):303–11.PubMedCrossRef
14.
Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004;95(1):9–20.PubMedCrossRef
15.
Sugiyama T, et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977–88.PubMedCrossRef
16.
17.
18.
Lazarus HM, et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995;16(4):557–64.PubMed
19.
Koc ON, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol. 2000;18(2):307–16.PubMedCrossRef
20.
Nassiri SM, Rahbarghazi R. Interactions of mesenchymal stem cells with endothelial cells. Stem Cells Dev. 2013;23:319–32.PubMedCrossRef
21.
Duffy GP, Herron CC. Mesenchymal stem cells to augment therapeutic angiogenesis in hind-limb ischemia models: how important is their source? Stem Cell Res Ther. 2013;4(5):131.PubMedPubMedCentralCrossRef
22.
23.
Carrion B, et al. Bone marrow-derived mesenchymal stem cells enhance angiogenesis via their alpha6beta1 integrin receptor. Exp Cell Res. 2013;319(19):2964–76.PubMedCrossRef
24.
Kong P, et al. Placenta mesenchymal stem cell accelerates wound healing by enhancing angiogenesis in diabetic Goto-Kakizaki (GK) rats. Biochem Biophys Res Commun. 2013;438(2):410–9.PubMedCrossRef
25.
Cunha FF, et al. A comparison of the reparative and angiogenic properties of mesenchymal stem cells derived from the bone marrow of BALB/c and C57/BL6 mice in a model of limb ischemia. Stem Cell Res Ther. 2013;4(4):86.PubMedPubMedCentralCrossRef
26.
Jin H, Sanberg PR, Henning RJ. Human umbilical cord blood mononuclear cell-conditioned media inhibits hypoxic-induced apoptosis in human coronary artery endothelial cells and cardiac myocytes by activation of the survival protein Akt. Cell Transplant. 2013;22(9):1637–50.PubMedCrossRef
27.
Doorn J, et al. Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev. 2012;18(2):101–15.PubMedCrossRef
28.
Cassatella MA, et al. Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells. 2011;29(6):1001–11.PubMedCrossRef
29.
Karaoz E, et al. Protection of rat pancreatic islet function and viability by coculture with rat bone marrow-derived mesenchymal stem cells. Cell Death Dis. 2010;1:e36.PubMedPubMedCentralCrossRef
30.
31.
Bartosh TJ, et al. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci USA. 2010;107(31):13724–9.PubMedCrossRef
32.
He A, et al. The antiapoptotic effect of mesenchymal stem cell transplantation on ischemic myocardium is enhanced by anoxic preconditioning. Can J Cardiol. 2009;25(6):353–8.PubMedPubMedCentralCrossRef
33.
Chen QQ, et al. Mesenchymal stem cells alleviate TNBS-induced colitis by modulating inflammatory and autoimmune responses. World J Gastroenterol. 2013;19(29):4702–17.PubMedPubMedCentralCrossRef
34.
Abumaree MH, et al. Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Rev. 2013;9(5):620–41.PubMedCrossRef
35.
Melief SM, et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells. 2013;31(9):1980–91.PubMedCrossRef
36.
Gu YZ, et al. Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells. Hum Immunol. 2013;74(3):267–76.PubMedCrossRef
37.
Hof-Nahor I, et al. Human mesenchymal stem cells shift CD8+ T cells towards a suppressive phenotype by inducing tolerogenic monocytes. J Cell Sci. 2012;125(Pt 19):4640–50.PubMedCrossRef
38.
Karlsson H, et al. Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. Clin Exp Immunol. 2012;167(3):543–55.PubMedPubMedCentralCrossRef
39.
Abumaree M, et al. Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev. 2012;8(2):375–92.PubMedCrossRef
40.
Li Y, et al. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice. Ann Hematol. 2011;90(8):873–85.PubMedCrossRef
41.
Zhou Y, et al. The therapeutic efficacy of human adipose tissue-derived mesenchymal stem cells on experimental autoimmune hearing loss in mice. Immunology. 2011;133(1):133–40.PubMedPubMedCentralCrossRef
42.
Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy. 2011;66(4):523–31.PubMedCrossRef
43.
Zanone MM, et al. Human mesenchymal stem cells modulate cellular immune response to islet antigen glutamic acid decarboxylase in type 1 diabetes. J Clin Endocrinol Metab. 2010;95(8):3788–97.PubMedCrossRef
44.
45.
Ding Y, et al. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes. 2009;58(8):1797–806.PubMedPubMedCentralCrossRef
46.
Gonzalez MA, et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 2009;60(4):1006–19.PubMedCrossRef
47.
Gonzalez MA, et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009;136(3):978–89.PubMedCrossRef
48.
Ryan JM, et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm. 2005;2:8.CrossRef
49.
Kim SJ, et al. Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. Trials. 2013;14(1):317.PubMedPubMedCentralCrossRef
50.
Lee JS, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28(6):1099–106.PubMedCrossRef
51.
Bang OY, et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005;57(6):874–82.PubMedCrossRef
52.
Bhasin A, et al. Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg. 2013;115(7):1003–8.PubMedCrossRef
53.
Bartunek J, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329–38.PubMedCrossRef
54.
Yang Z, et al. A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery. Cardiovasc Ther. 2010;28(6):380–5.PubMedCrossRef
55.
Weiss DJ, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143(6):1590–8.PubMedCrossRef
56.
Shi M, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 2012;1(10):725–31.PubMedPubMedCentralCrossRef
57.
Horwitz EM, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99(13):8932–7.PubMedCrossRef
58.
Koc ON, et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 2002;30(4):215–22.PubMedCrossRef
59.
Ichim TE, et al. Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol. 2010;260(2):75–82.PubMedCrossRef
60.
Landen NX, Li D, Stahle M. Transition from inflammation to proliferation: a critical step during wound healing. Cell Mol Life Sci. 2016;73(20):3861–85.PubMedPubMedCentralCrossRef
61.
62.
Ho S, Marcal H, Foster LJ. Towards scarless wound healing: a comparison of protein expression between human, adult and foetal fibroblasts. Biomed Res Int. 2014;2014:676493.PubMedPubMedCentral
63.
64.
Chang Y, Li H, Guo Z. Mesenchymal stem cell-like properties in fibroblasts. Cell Physiol Biochem. 2014;34(3):703–14.PubMedCrossRef
65.
Phipps RP, et al. Characterization of two major populations of lung fibroblasts: distinguishing morphology and discordant display of Thy 1 and class II MHC. Am J Respir Cell Mol Biol. 1989;1(1):65–74.PubMedCrossRef
66.
Akamine A, Raghu G, Narayanan AS. Human lung fibroblast subpopulations with different C1q binding and functional properties. Am J Respir Cell Mol Biol. 1992;6(4):382–9.PubMedCrossRef
67.
Etikala A, et al. LR8 expression in fibroblasts of healthy and fibrotic human tissues. Biochem Biophys Rep. 2017;10:165–71.PubMedPubMedCentral
68.
Koumas L, et al. Fibroblast heterogeneity: existence of functionally distinct Thy 1(+) and Thy 1(−) human female reproductive tract fibroblasts. Am J Pathol. 2001;159(3):925–35.PubMedPubMedCentralCrossRef
69.
Fries KM, et al. CD40 expression by human fibroblasts. Clin Immunol Immunopathol. 1995;77(1):42–51.PubMedCrossRef
70.
Fries KM, et al. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin Immunol Immunopathol. 1994;72(3):283–92.PubMedCrossRef
71.
Lekic PC, Pender N, McCulloch CA. Is fibroblast heterogeneity relevant to the health, diseases, and treatments of periodontal tissues? Crit Rev Oral Biol Med. 1997;8(3):253–68.PubMedCrossRef
72.
73.
Chang HY, et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA. 2002;99(20):12877–82.PubMedCrossRef
74.
Wang N, Stamenovic D. Mechanics of vimentin intermediate filaments. J Muscle Res Cell Motil. 2002;23(5–6):535–40.PubMedCrossRef
75.
76.
Lucotte B, et al. Stress conditions increase vimentin cleavage by Omi/HtrA2 protease in human primary neurons and differentiated neuroblastoma cells. Mol Neurobiol. 2015;52(3):1077–92.PubMedCrossRef
77.
78.
79.
Poudel B, et al. Collagen I enhances functional activities of human monocyte-derived dendritic cells via discoidin domain receptor 2. Cell Immunol. 2012;278(1–2):95–102.PubMedCrossRef
80.
Lee JE, et al. Discoidin domain receptor 2 is involved in the activation of bone marrow-derived dendritic cells caused by type I collagen. Biochem Biophys Res Commun. 2007;352(1):244–50.PubMedCrossRef
81.
82.
Zucchini A, et al. Cd90. J Biol Regul Homeost Agents. 2001;15(1):82–5.PubMed
83.
Baglole CJ, et al. Isolation and phenotypic characterization of lung fibroblasts. Methods Mol Med. 2005;117:115–27.PubMed
84.
Hagood JS, et al. Differential expression of platelet-derived growth factor-alpha receptor by Thy-1(−) and Thy-1(+) lung fibroblasts. Am J Physiol. 1999;277(1 Pt 1):L218–24.PubMed
85.
Koumas L, Smith TJ, Phipps RP. Fibroblast subsets in the human orbit: Thy-1 + and Thy-1- subpopulations exhibit distinct phenotypes. Eur J Immunol. 2002;32(2):477–85.PubMedCrossRef
86.
87.
Huynh PT, et al. CD90(+) stromal cells are the major source of IL-6, which supports cancer stem-like cells and inflammation in colorectal cancer. Int J Cancer. 2016;138(8):1971–81.PubMedCrossRef
88.
Singh M, et al. Chondrogenic differentiation of neonatal human dermal fibroblasts encapsulated in alginate beads with hydrostatic compression under hypoxic conditions in the presence of bone morphogenetic protein-2. J Biomed Mater Res A. 2011;98(3):412–24.PubMedCrossRef
89.
Chee A, et al. Cell therapy with human dermal fibroblasts Enhances intervertebral disk repair and decreases inflammation in the rabbit model. Global Spine J. 2016;6(8):771–9.PubMedPubMedCentralCrossRef
90.
91.
Sabatini F, et al. Human bronchial fibroblasts exhibit a mesenchymal stem cell phenotype and multilineage differentiating potentialities. Lab Invest. 2005;85(8):962–71.PubMedCrossRef
92.
Lorenz K, et al. Multilineage differentiation potential of human dermal skin-derived fibroblasts. Exp Dermatol. 2008;17(11):925–32.PubMedCrossRef
93.
Huang HI, et al. Multilineage differentiation potential of fibroblast-like stromal cells derived from human skin. Tissue Eng Part A. 2010;16(5):1491–501.PubMedCrossRef
94.
Chandravanshi B, Bhonde R. Reprogramming mouse embryo fibroblasts to functional islets without genetic manipulation. J Cell Physiol. 2018;233(2):1627–37.PubMedCrossRef
95.
Huang HI, et al. Human foreskin fibroblast-like stromal cells can differentiate into functional hepatocytic cells. Cell Biol Int. 2013;37(12):1308–19.PubMedCrossRef
96.
Locatelli F, et al. Remestemcel-L for the treatment of graft versus host disease. Expert Rev Clin Immunol. 2017;13(1):43–56.PubMedCrossRef
97.
Newell LF, Deans RJ, Maziarz RT. Adult adherent stromal cells in the management of graft-versus-host disease. Expert Opin Biol Ther. 2014;14(2):231–46.PubMedCrossRef
98.
Connick P, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11(2):150–6.PubMedPubMedCentralCrossRef
99.
Cohen JA, et al. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler. 2017;24:501–11.PubMedCrossRef
100.
Keane C, Jerkic M, Laffey JG. Stem cell-based therapies for sepsis. Anesthesiology. 2017;127(6):1017–34.PubMedCrossRef
101.
Cai J, et al. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established Type 1 Diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care. 2016;39(1):149–57.PubMedCrossRef
102.
Alvaro-Gracia JM, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis. 2017;76(1):196–202.PubMedCrossRef
103.
Cappellesso-Fleury S, et al. Human fibroblasts share immunosuppressive properties with bone marrow mesenchymal stem cells. J Clin Immunol. 2010;30(4):607–19.PubMedCrossRef
104.
Wada N, Bartold PM, Gronthos S. Human foreskin fibroblasts exert immunomodulatory properties by a different mechanism to bone marrow stromal/stem cells. Stem Cells Dev. 2011;20(4):647–59.PubMedCrossRef
105.
106.
Kuroyanagi Y, et al. A cultured skin substitute composed of fibroblasts and keratinocytes with a collagen matrix: preliminary results of clinical trials. Ann Plast Surg. 1993;31(4):340–9 (Discussion 349–351).PubMedCrossRef
107.
Hart CE, Loewen-Rodriguez A, Lessem J. Dermagraft: use in the treatment of chronic wounds. Adv Wound Care. 2012;1(3):138–41.CrossRef
108.
Venugopal SS, et al. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2013;69(6):898.e7–908.e7.CrossRef
109.
Petrof G, et al. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. Br J Dermatol. 2013;169(5):1025–33.PubMedCrossRef
110.
Milinkovic I, et al. Clinical application of autologous fibroblast cell culture in gingival recession treatment. J Periodontal Res. 2015;50(3):363–70.PubMedCrossRef
111.
Dominiak M, et al. The clinical efficacy of primary culture of human fibroblasts in gingival augmentation procedures-a preliminary report. Ann Anat. 2012;194(6):502–7.PubMedCrossRef
112.
Smith SR, et al. A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles. Dermatol Surg. 2012;38(7 Pt 2):1234–43.PubMedCrossRef
113.
Munavalli GS, et al. Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi-site, prospective, double blind, placebo-controlled clinical trial. Dermatol Surg. 2013;39(8):1226–36.PubMedPubMedCentralCrossRef
114.
Weiss RA. Autologous cell therapy: will it replace dermal fillers? Facial Plast Surg Clin N Am. 2013;21(2):299–304.CrossRef
Metadata
Title
Fibroblasts as a practical alternative to mesenchymal stem cells
Authors
Thomas E. Ichim
Pete O’Heeron
Santosh Kesari
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2018
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-018-1536-1

Other articles of this Issue 1/2018

Journal of Translational Medicine 1/2018 Go to the issue

Research

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients

Research

Genetic characterisation of molecular targets in carcinoma of unknown primary

Review

Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies

Research

Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis

Commentary

High density lipoprotein cholesterol and proteome in SR-B1 KO mice: lost in precipitation

Research

Increased citrullination and expression of peptidylarginine deiminases independently of P. gingivalis and A. actinomycetemcomitans in gingival tissue of patients with periodontitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits